Cargando…
The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primar...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807368/ https://www.ncbi.nlm.nih.gov/pubmed/31767164 http://dx.doi.org/10.1016/j.molmet.2019.09.006 |
_version_ | 1783461705377906688 |
---|---|
author | Antonellis, Patrick J. Droz, Brian A. Cosgrove, Richard O'Farrell, Libbey S. Coskun, Tamer Perfield, James W. Bauer, Steven Wade, Mark Chouinard, Tara E. Brozinick, Joseph T. Adams, Andrew C. Samms, Ricardo J. |
author_facet | Antonellis, Patrick J. Droz, Brian A. Cosgrove, Richard O'Farrell, Libbey S. Coskun, Tamer Perfield, James W. Bauer, Steven Wade, Mark Chouinard, Tara E. Brozinick, Joseph T. Adams, Andrew C. Samms, Ricardo J. |
author_sort | Antonellis, Patrick J. |
collection | PubMed |
description | OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primary target organ of FGF19 is the liver, where it regulates bile acid homeostasis in response to nutrient absorption. In contrast, the broader pharmacologic actions of FGF19 are proposed to be driven, in part, by the recruitment of the thermogenic protein uncoupling protein 1 (UCP1) in white and brown adipose tissue. However, the precise contribution of UCP1-dependent thermogenesis to the therapeutic actions of FGF19 has not been critically evaluated. METHODS: Using WT and germline UCP1 knockout mice, the primary objective of the current investigation was to determine the in vivo pharmacology of FGF19, focusing on its thermogenic and anti-obesity activity. RESULTS: We report that FGF19 induced mRNA expression of UCP1 in adipose tissue and show that this effect is required for FGF19 to increase caloric expenditure. However, we demonstrate that neither UCP1 induction nor an elevation in caloric expenditure are necessary for FGF19 to induce weight loss in obese mice. In contrast, the anti-obesity action of FGF19 appeared to be associated with its known physiological role. In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. CONCLUSION: Taken together, we report that the anti-obesity effect of FGF19 occurs in the absence of UCP1. Our data suggest that the primary way in which exogenous FGF19 lowers body weight in mice may be through the inhibition of bile acid synthesis and subsequently a reduction of dietary lipid absorption. |
format | Online Article Text |
id | pubmed-6807368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68073682019-10-28 The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis Antonellis, Patrick J. Droz, Brian A. Cosgrove, Richard O'Farrell, Libbey S. Coskun, Tamer Perfield, James W. Bauer, Steven Wade, Mark Chouinard, Tara E. Brozinick, Joseph T. Adams, Andrew C. Samms, Ricardo J. Mol Metab Brief Communication OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primary target organ of FGF19 is the liver, where it regulates bile acid homeostasis in response to nutrient absorption. In contrast, the broader pharmacologic actions of FGF19 are proposed to be driven, in part, by the recruitment of the thermogenic protein uncoupling protein 1 (UCP1) in white and brown adipose tissue. However, the precise contribution of UCP1-dependent thermogenesis to the therapeutic actions of FGF19 has not been critically evaluated. METHODS: Using WT and germline UCP1 knockout mice, the primary objective of the current investigation was to determine the in vivo pharmacology of FGF19, focusing on its thermogenic and anti-obesity activity. RESULTS: We report that FGF19 induced mRNA expression of UCP1 in adipose tissue and show that this effect is required for FGF19 to increase caloric expenditure. However, we demonstrate that neither UCP1 induction nor an elevation in caloric expenditure are necessary for FGF19 to induce weight loss in obese mice. In contrast, the anti-obesity action of FGF19 appeared to be associated with its known physiological role. In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. CONCLUSION: Taken together, we report that the anti-obesity effect of FGF19 occurs in the absence of UCP1. Our data suggest that the primary way in which exogenous FGF19 lowers body weight in mice may be through the inhibition of bile acid synthesis and subsequently a reduction of dietary lipid absorption. Elsevier 2019-09-29 /pmc/articles/PMC6807368/ /pubmed/31767164 http://dx.doi.org/10.1016/j.molmet.2019.09.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Communication Antonellis, Patrick J. Droz, Brian A. Cosgrove, Richard O'Farrell, Libbey S. Coskun, Tamer Perfield, James W. Bauer, Steven Wade, Mark Chouinard, Tara E. Brozinick, Joseph T. Adams, Andrew C. Samms, Ricardo J. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title | The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title_full | The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title_fullStr | The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title_full_unstemmed | The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title_short | The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis |
title_sort | anti-obesity effect of fgf19 does not require ucp1-dependent thermogenesis |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807368/ https://www.ncbi.nlm.nih.gov/pubmed/31767164 http://dx.doi.org/10.1016/j.molmet.2019.09.006 |
work_keys_str_mv | AT antonellispatrickj theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT drozbriana theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT cosgroverichard theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT ofarrelllibbeys theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT coskuntamer theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT perfieldjamesw theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT bauersteven theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT wademark theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT chouinardtarae theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT brozinickjosepht theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT adamsandrewc theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT sammsricardoj theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT antonellispatrickj antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT drozbriana antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT cosgroverichard antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT ofarrelllibbeys antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT coskuntamer antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT perfieldjamesw antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT bauersteven antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT wademark antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT chouinardtarae antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT brozinickjosepht antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT adamsandrewc antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis AT sammsricardoj antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis |